XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W.L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Benjamin M. ParsonsJ. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu*, Ken H. Young*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science